-
Number of Participants With Successful Extubation
Time frame: From day of randomization to day 14 post randomization
Successful extubation during the intervention period, defined as remaining extubated for greater than or equal to 1 week, including greater than or equal to 3 days after the last dose of study medication. An extubation attempt was required after 72 hours of study drug and 24 hours after meeting the following: FiO2 less than 0.40 to maintain a saturation of greater than or equal to 88 percent, mean airway pressure less than 8 cm H2O, and hemodynamically stable in the opinion of the clinical team.
-
Total Deaths Before Discharge
Time frame: From day of randomization to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Infant died before discharge home.
-
Number of Participants With Bronchopulmonary Dysplasia (BPD) Grade at 36 Weeks Postmenstrual Age
Time frame: At 36 weeks postmenstrual age
BPD grade at 36 weeks postmenstrual age. BPD grades are defined as: 1. No support/room air; 2. Nasal cannula (NC) O2 less than or equal to 2L; 3. NC O2 greater than 2L or CPAP/NIPPV; 4. Invasive PPV
-
Days of Mechanical Ventilation to 36 Weeks Postmenstrual Age (PMA)
Time frame: From birth to 36 weeks postmenstrual age
Number of days on mechanical ventilation (using high frequency ventilator or conventional ventilator)
-
Duration of Oxygen Supplementation up to Status
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of days of oxygen supplementation from birth to discharge home
-
Length of Hospital Stay in Days Among Survivors to Discharge
Time frame: From birth up to one year
Number of days infant stayed in hospitals, among those who survived to discharge
-
Number of Participants With Dexamethasone Given Before 36 Weeks Postmenstrual Age (PMA)
Time frame: From birth to 36 weeks postmenstrual age
Infant received dexamethasone anytime before 36 weeks postmenstrual age.
-
Number of Participants With Normal/Mild, Moderate or Severe/Profound NDI
Time frame: At 22-26 months corrected age
Severity of neurodevelopmental impairment, defined as one or more of: Bayley Scales of Infant Development-III (Bayley-III) cognitive score <85 (standardized mean 100, SD 15, range 55-145), Bayley-III motor score <85 (standardized mean 100, range 45-155), Gross Motor Function Classification System (GMFCS) level ≥2, severe vision impairment in both eyes (consistent with refraction <20-200), or bilateral hearing impairment with or without amplification (by report).
Bayley-III = Bayley Scales of Infant Development III (Cognitive score standardized mean 100, SD 15, range 55-145 motor score standardized mean 100, range 45-155; higher score indicates better performance (20))
-
Number of Participants With Gross Motor Function Greater Than or Equal to Level 2
Time frame: At 22-26 months corrected age
Number of infants with Gross Motor Function Classification System (GMFCS) level greater than or equal to II (on a scale from level I to V; I=normal and progressively higher levels indicate greater impairment)
-
Number of Participants With Moderate-severe Cerebral Palsy
Time frame: At 22-26 months corrected age
Number of infants with moderate or severe grade of cerebral palsy. Cerebral Palsy was diagnosed when there were definite abnormalities observed in the neuromotor exam, and functional challenges as classified by GMFCS level, and classified as moderate if GMFCS level was II or III and severe if level IV or V (40).
-
Number of Participants With Severe Hearing Impairment (by Report)
Time frame: At 22-26 months corrected age
Number of infants with bilateral hearing impairment with or without amplification (by report)
-
Number of Participants With no/Some Functional Vision
Time frame: At 22-26 months corrected age
Number of infants with severe vision impairment in both eyes (consistent with refraction less than 20-200)
-
Weight Growth Measure Following Extremely Preterm Birth
Time frame: At 36 weeks post-menstrual age
This is measured as the weight Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average weight, and negative scores denote less than average weight.
-
Follow-up Weight Growth Measure Following Extremely Preterm Birth
Time frame: At 22-26 months corrected age
This is measured as the weight Z-score at 22-26 months corrected age. The Z-score is determined using the WHO weight-for-age chart, and is derived from a standardized normal distribution, where 0 designates average weight-for-age, and negative scores denote less than average weight-for-age.
-
Length Growth Measure Following Extremely Preterm Birth
Time frame: At 36 weeks post-menstrual age
This is measured as the length Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average length, and negative scores denote less than average length.
-
Follow-up Length Growth Measure Following Extremely Preterm Birth
Time frame: At 22-26 months corrected age
This is measured as the length Z-score at 22-26 months corrected age. The Z-score is determined using the WHO length-for-age chart, and is derived from a standardized normal distribution, where 0 designates average length-for-age, and negative scores denote less than average length-for-age.
-
Head Circumference Growth Measure Following Extremely Preterm Birth
Time frame: At 36 weeks post-menstrual age
This is measured as the head circumference Z-score at 36 weeks postmenstrual age. The Z-score is derived using Fenton growth curves, and follows a standardized normal distribution with a mean 0. A z-score of 0 designates average head circumference, and negative scores denote less than average head circumference.
-
Follow-up Head Circumference Growth Measure Following Extremely Preterm Birth
Time frame: At 22-26 months corrected age
This is measured as the head circumference Z-score at 22-26 months corrected age. The Z-score is determined using the WHO head circumference-for-age chart, and is derived from a standardized normal distribution, where 0 designates average head circumference-for-age, and negative scores denote less than average head circumference-for-age.
-
Number of Participants With Bronchopulmonary Dysplasia (BPD) Grade 40 Weeks Postmenstrual Age
Time frame: At 40 weeks post menstrual age
BPD grade at 40 weeks postmenstrual age. BPD grades are defined as: 1. No support/room air; 2. Nasal cannula (NC) O2 less than or equal to 2L; 3. NC O2 greater than 2L or CPAP/NIPPV; 4. Invasive PPV
-
Days of Mechanical Ventilation up to Status
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of days on mechanical ventilation (using high frequency ventilator or conventional ventilator) up to status
-
Duration of Oxygen Supplementation Among Survivors to 36 Weeks
Time frame: From birth to 36 weeks postmenstrual age
Number of days of oxygen supplementation from birth to 36 weeks post menstrual age
-
Duration of Invasive Positive Pressure Ventilation (PPV) After Postnatal Day 14
Time frame: From postnatal day 15 to 36 weeks post menstrual age or Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of days on invasive PPV after postnatal day 14
-
Duration of Non-invasive Positive Pressure Ventilation (PPV) (Nasal IPPV/CPAP) After Postnatal Day 14
Time frame: From postnatal day 15 to 36 weeks post menstrual age or Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of days of non-invasive PPV after postnatal day 14
-
Number of Participants Who Received Inhaled Glucocorticoids During Study Period
Time frame: From randomization to day 14 post randomization
Number of infants who received Inhaled glucocorticoids during the study intervention period
-
Number of Participants Who Received Other Systemic Glucocorticoids During Study Period
Time frame: From randomization to day 14 post randomization
Number of infants who received other systemic glucocorticoids during the study intervention period
-
Number of Days Dexamethasone Given Before 36 Weeks PMA
Time frame: From birth to 36 weeks postmenstrual age
Number of days infant received dexamethasone anytime before 36 weeks postmenstrual age.
-
Number of Participants With Patent Ductus Arteriosus (PDA) Treated With Medication or Surgery
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants with a Patent Ductus Arteriosus (PDA) that was treated with medicine or surgery
-
Number of Participants Diagnosed With Necrotizing Enterocolitis (NEC)
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants diagnosed with Necrotizing Enterocolitis (NEC)
-
Number of Participants With Retinopathy of Prematurity (ROP) Stage 3 or Worse
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants diagnosed with ROP stage 3 or worse in either eye. ROP stage 3 or worse is determined based on the extent of extraretinal fibrovascular proliferation. Higher stages of ROP indicate a worse outcome; the stages range from 1 for "mild" disease, to 5 for "severe" disease.
-
Number of Participants Receiving Therapy for Retinopathy of Prematurity (ROP)
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants receiving therapy for Retinopathy of prematurity (ROP)
-
Number of Participants With Severe Intraventricular Hemorrhage (IVH)
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants with severe IVH, grade 3 or 4. Severity of IVH is hierarchical. Grade 3 occurs when the ventricular size is enlarged and blood/echodensity is in the ventricle. Grade 4 occurs when blood/echodensity is in the parenchyma.
-
Number of Participants With Periventricular Leukomalacia
Time frame: From birth to Neonatal Research Network NRN infant status i.e., the first occurring of: discharge home, death, transfer, or 120 days following birth
Number of infants with Periventricular leukomalacia
-
Number of Participants With Neurodevelopmental Impairment (NDI)
Time frame: At 22-26 months corrected age
Number of infants with NDI. NDI is defined as defined as any of: Bayley Scales of Infant and Toddler Development-III (Bayley-III) cognitive composite score less than 85 (standardized mean 100, SD 15, range 55-145) or motor composite score less than 85 (standardized mean 100, range 45-155) (lower scores indicating greater impairment), Gross Motor Function Classification System (GMFCS) level greater than or equal to II (on a scale from level I to V; I=normal and progressively higher levels indicate greater impairment), severe vision impairment in both eyes (consistent with refraction less than 20-200), or bilateral hearing impairment with or without amplification (by report).
-
Number of Participants With a Bayley Scales of Infant Development (BSID) Cognitive Composite Score Less Than 85
Time frame: At 22-26 months corrected age
Number of infants with a BSID-III cognitive composite score less than 85. (standardized mean 100, SD 15, range 55-145). Higher scores indicate better performance. Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.
-
Number of Participants With a Bayley Scales of Infant Development (BSID) Cognitive Composite Score Less Than 70
Time frame: At 22-26 months corrected age
Number of infants with a BSID-III cognitive composite score less than 70. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.
-
Number of Participants With a Bayley Scales of Infant Development (BSID) Motor Composite Score Less Than 85
Time frame: At 22-26 months corrected age
Number of infants with a BSID-III motor composite score less than 85. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 85 are less than 1 standard deviation below the mean of 100.
-
Number of Participants With a Bayley Scales of Infant Development (BSID) Motor Composite Score Less Than 70
Time frame: At 22-26 months corrected age
Number of infants with a BSID-III motor composite score less than 70. (standardized mean 100, SD 15, range 55-145). Composite BSID-III scores of less than 70 are less than 2 standard deviations below the mean of 100.
-
Number of Participants With Any Cerebral Palsy
Time frame: At 22-26 months corrected age
Number of infants with cerebral palsy. Cerebral Palsy was diagnosed when there were definite abnormalities observed in the neuromotor exam, and functional challenges as classified by GMFCS level, and classified as moderate if GMFCS level was II or III and severe if level IV or V (40).